



## NOTIFICATION TO STOCK EXCHANGE

### COMPANY STATEMENT

#### **Biocon Pharma Limited Receives US FDA Approval for Sacubitril/Valsartan Tablets**

**Bengaluru, Karnataka, India, September 01, 2024**

*"This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg strengths, from the U.S. Food and Drug Administration (US FDA). Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization. This medicine is also used to treat paediatric patients over the age of one year.*

*The approval further adds to Biocon's portfolio of vertically integrated, complex drug products."*